Amplia Therapeutics Says Preclinical Data Showed Drug Candidate Boosts kRAS Inhibitors in Cancer Treatment; Shares Fall 9%

MT Newswires Live

03/09

Amplia Therapeutics (ASX:ATX) said preclinical data showed that its focal adhesion kinase inhibitor narmafotinib boosts the activity of a class of drugs called kRAS inhibitors in various models of cancer, according to a Monday Australian bourse filing.

Narmafotinib blocks resistance pathways that can emerge with kRAS inhibitor treatment, it noted.

The combination led to improved responsiveness to chemotherapy in preclinical models, and narmafotinib combined with pan-RAS inhibitor improves tumor growth inhibition, the company said.

Tumors in ovarian cancer treated with narmafotinib combined with pegylated liposomal doxorubicin reduced KRAS signaling, the company added.

Amplia Therapeutics' shares fell 9% in recent trading on Monday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2618619241"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618619241\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618619241?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-09 12:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618619241","market":"sh","top_or_hot":-1,"title":"Amplia Therapeutics Says Preclinical Data Showed Drug Candidate Boosts kRAS Inhibitors in Cancer Treatment; Shares Fall 9%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ATX.AU\">Amplia Therapeutics</a> (ASX:ATX) said preclinical data showed that its focal adhesion kinase inhibitor narmafotinib boosts the activity of a class of drugs called kRAS inhibitors in various models of cancer, according to a Monday Australian bourse filing.</p><p>Narmafotinib blocks resistance pathways that can emerge with kRAS inhibitor treatment, it noted.</p><p>The combination led to improved responsiveness to chemotherapy in preclinical models, and narmafotinib combined with pan-RAS inhibitor improves tumor growth inhibition, the company said.</p><p>Tumors in ovarian cancer treated with narmafotinib combined with pegylated liposomal doxorubicin reduced KRAS signaling, the company added.</p><p>Amplia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' shares fell 9% in recent trading on Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amplia Therapeutics Says Preclinical Data Showed Drug Candidate Boosts kRAS Inhibitors in Cancer Treatment; Shares Fall 9%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmplia Therapeutics Says Preclinical Data Showed Drug Candidate Boosts kRAS Inhibitors in Cancer Treatment; Shares Fall 9%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-09 12:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ATX.AU\">Amplia Therapeutics</a> (ASX:ATX) said preclinical data showed that its focal adhesion kinase inhibitor narmafotinib boosts the activity of a class of drugs called kRAS inhibitors in various models of cancer, according to a Monday Australian bourse filing.</p><p>Narmafotinib blocks resistance pathways that can emerge with kRAS inhibitor treatment, it noted.</p><p>The combination led to improved responsiveness to chemotherapy in preclinical models, and narmafotinib combined with pan-RAS inhibitor improves tumor growth inhibition, the company said.</p><p>Tumors in ovarian cancer treated with narmafotinib combined with pegylated liposomal doxorubicin reduced KRAS signaling, the company added.</p><p>Amplia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' shares fell 9% in recent trading on Monday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2618619241","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618619241","pubTimestamp":1773029208,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Amplia Therapeutics (ASX:ATX) said preclinical data showed that its focal adhesion kinase inhibitor narmafotinib boosts the activity of a class of drugs called kRAS inhibitors in various models of can","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LENZ":"Therapeutics","BK7067":"生物科技","BK4007":"制药","ATX.AU":"AMPLIA THERAPEUTICS LTD","BK4539":"次新股"},"translate_title":"Amplia Therapeutics表示，临床前数据显示候选药物可增强kRAS抑制剂在癌症治疗中的作用；股价下跌9%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"ATX.AU":1},"content_text":"Amplia Therapeutics (ASX:ATX) said preclinical data showed that its focal adhesion kinase inhibitor narmafotinib boosts the activity of a class of drugs called kRAS inhibitors in various models of cancer, according to a Monday Australian bourse filing.Narmafotinib blocks resistance pathways that can emerge with kRAS inhibitor treatment, it noted.The combination led to improved responsiveness to chemotherapy in preclinical models, and narmafotinib combined with pan-RAS inhibitor improves tumor growth inhibition, the company said.Tumors in ovarian cancer treated with narmafotinib combined with pegylated liposomal doxorubicin reduced KRAS signaling, the company added.Amplia Therapeutics' shares fell 9% in recent trading on Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}